A case of type 1 diabetes caused by gastric cancer treated with Sintilimab

VernacularTitle:信迪利单抗治疗胃癌致1型糖尿病1例
Author: Yihan GAO ¹ ; Jingyu CHEN ; Haoyu FU ; Junquan YANG
Author Information

1. 河北省唐山市人民医院放化一科，唐山　063001
Keywords: Gastric tumors; Immune checkpoint inhibitors; Adverse immune reactions; Type 1 diabetes; Sintilimab
From: Clinical Medicine of China 2024;40(1):70-72
CountryChina
Language:Chinese
Abstract: Immune checkpoint inhibitors (ICIs) are currently used in the treatment of various tumors and play an important role in tumor treatment, resulting in many adverse reactions related to the immune system. Type 1 diabetes (T1DM) is a rare endocrine system complication, which is rarely reported at present. We report a case of T1DM after using ICIs to treat gastric cancer. The patient was a 34 year old male who developed diabetes ketoacidosis after 206 days of sintilimab monoclonal antibody use, with fasting blood glucose of 15.78 mmol/L and glycosylated hemoglobin of 8.6%. Islet related antibody: Glutamate decarboxylase antibody: 119.2 IU/mL; Insulin antibody:<2 IU/L. Fasting insulin: 0.21 mU/L; Fasting C-peptide: 0.12 μg/L. Through the analysis of patients' clinical data, it aims to improve clinicians' understanding of immune related type 1 diabetes and provide ideas for correct diagnosis and treatment.